Pre-clinical Safety & Toxicology

This workflow enables pharmaceutical companies to enhance early-stage decision-making, minimize clinical trial failures, lower experimental costs, and improve risk prediction accuracy.

Understanding of mode of action (MoA), including target-based toxicity, which assesses whether the drug target is linked to known toxic effects, and adverse events caused by off-target effects.

Understanding of Pharmacokinetics (PK) and Pharmacodynamics (PD). Establishing safety margins, which includes determining the No Observed Adverse Effect Level (NOAEL) and Maximum Tolerated Dose (MTD) to define safe dosage levels.

Organ-specific toxicity analysis, with endpoints in hepatotoxicity, cardiotoxicity, skin toxicity and neurotoxicity. This includes multimodal data analysis for liver damage prediction, and impact on the nervous system, skin, heart rhythm and function.